FDG PET/CT for Lung Cancer

Recruiting in Palo Alto (17 mi)

Overseen byDaniel Pryma, MD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: Abramson Cancer Center of the University of Pennsylvania

No Placebo Group

Approved in 6 Jurisdictions

Trial Summary

What is the purpose of this trial?Prospective study of the effects of image acquisition and reconstruction parameters on accuracy of FDG PET/CT mediastinal nodal staging in NSCLC

Eligibility Criteria

This trial is for adults over 18 with a diagnosis of non-small cell lung cancer (NSCLC) who need an FDG PET/CT scan as part of their usual care. They must understand the study's research nature and agree to it in writing. It's not for those who can't handle extra imaging time, economically disadvantaged individuals, children, neonates, prisoners, or mentally disabled persons.

Inclusion Criteria

I am 18 years old or older.

I have NSCLC and am scheduled for a PET/CT scan.

Participants must be informed of the investigational nature of this study and provide written informed consent in accordance with institutional and federal guidelines prior to study-specific procedures.

Exclusion Criteria

I am not a child, fetus, neonate, or prisoner.

Inability to tolerate additional imaging time in the opinion of the investigator or treating physician

Individuals who are mentally disabled

Participant Groups

The study is looking at how different ways of taking pictures and processing them affect the accuracy of FDG PET/CT scans used to figure out if NSCLC has spread to lymph nodes in the chest area. This is a forward-looking study that tracks participants over time.

1Treatment groups

Experimental Treatment

Group I: PET imagingExperimental Treatment1 Intervention

PET imaging